Education
About Us
Working with TipRanks
Follow Us
Charles River Laboratories Intl (CRL)
:CRL
Earnings Data
Report Date
Feb 18, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
2.35Last Year’s EPS
2.66Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there were positive developments such as improvements in biotech funding, strategic portfolio adjustments, and RMS segment growth, these were countered by revenue declines in key segments, a decrease in operating margins, and a drop in earnings per share.Company Guidance
Strategic Review and Portfolio Strengthening
The strategic review led to a focus on strengthening core markets, divesting underperforming assets, and a new $1 billion stock repurchase authorization. The board supports the strategic direction, aiming to increase non-GAAP earnings by at least $0.30 per share through divestitures by mid-2026.
Improvement in Biotech Funding Environment
Biotech funding showed significant improvement in Q3, with October being the second-highest month in biotech history. This indicates an upward trend in potential client demand.
RMS Segment Performance
RMS revenue increased by 6.5% on an organic basis compared to the third quarter of 2024, driven by favorable timing of NHP shipments.
DSA Proposal Activity and Bookings
Proposal activity improved, particularly for biotech clients, with high single-digit increases both year-over-year and sequentially.
Free Cash Flow Improvement
Free cash flow improved sequentially by $8.9 million, reflecting disciplined capital spending and working capital management.
NAMs Capabilities Development
Charles River is developing NAMs capabilities, including next-generation sequencing solutions and animal-free products, indicating a forward-looking approach in innovation.
CRL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | $177.85 | $167.70 | -5.71% |
Aug 06, 2025 | $167.49 | $150.33 | -10.25% |
May 07, 2025 | $115.41 | $136.97 | +18.68% |
Feb 19, 2025 | $154.39 | $165.00 | +6.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Charles River Laboratories Intl (CRL) report earnings?
Charles River Laboratories Intl (CRL) is schdueled to report earning on Feb 18, 2026, Before Open (Confirmed).
What is Charles River Laboratories Intl (CRL) earnings time?
Charles River Laboratories Intl (CRL) earnings time is at Feb 18, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRL EPS forecast?
CRL EPS forecast for the fiscal quarter 2025 (Q4) is 2.35.
